PTCT Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
360.5M
+32.3%
272.6M
+65.5%
164.7M
-22.0%
211.0M
+18.0%
178.9M
Cost of Revenue
19.9M
-28.9%
28.0M
+303.3%
7.0M
-56.0%
15.8M
+38.2%
11.4M
Gross Profit
340.6M
+39.3%
244.5M
+55.0%
157.7M
-19.2%
195.2M
+16.6%
167.5M
Operating Expenses
191.6M
-4.0%
199.6M
-12.6%
228.3M
+18.8%
192.2M
-5.0%
202.4M
R&D
99.2M
-1.7%
100.9M
-24.2%
133.1M
+32.9%
100.2M
-11.4%
113.0M
SG&A
80.6M
-6.4%
86.2M
-11.0%
96.9M
+15.3%
84.0M
-1.4%
85.3M
Operating Income
149.0M
+231.4%
45.0M
+163.7%
-70549000
-2439.2%
3.0M
+108.6%
-34957000
EBITDA
164.9M
+168.9%
61.3M
+190.2%
-67922000
-565.3%
14.6M
+153.5%
-27275000
Net Income
83.5M
+3072.4%
-2809000
+97.9%
-134965000
-949.1%
15.9M
+124.5%
-64849000
EPS (Basic)
$1.01
+3466.7%
$-0.03
+98.1%
$-1.62
-910.0%
$0.20
+124.1%
$-0.83
EPS (Diluted)
$0.92
+3166.7%
$-0.03
+97.7%
$-1.33
-765.0%
$0.20
+124.1%
$-0.83
Shares (Diluted)
92.0M
+11.5%
82.5M
-18.8%
101.6M
+16.6%
87.1M
+11.5%
78.2M
PTC Therapeutics (PTCT) โ€” Financials